Journal of Hepatology

Print ISSN
Electronic ISSN
Impact factor
Usage rank
Article count
Free count
Free percentage
PDFs via platforms
Gale, Rcgp, Ingenta, and Sciencedirect

  1. Corrigendum to “Long-term cannabinoid type 2 receptor agonist therapy decreases bacterial translocation in rats with cirrhosis and ascites” [J Hepatol 2014;61:1004–1013]

    Journal of Hepatology 62(5) (2015)

  2. From the Editor’s desk…: May 2015

    Journal of Hepatology 62(5):991 (2015)

    Daily drinking and consuming more than 14 units of alcohol per week increases risk of alcoholic cirrhosis Deaths from liver disease have increased dramatically over the past 30years and one of the culprits for this increase is excessive alcohol consump...
  3. Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites

    Journal of Hepatology 62(4):968 (2015)

  4. The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease

    Journal of Hepatology 62(4):841 (2015)

    Background & Aims Patients with non-alcoholic fatty liver disease (NAFLD) are thought to be at increased risk of cardiovascular morbidity and mortality. However, the relationships between NAFLD and subclinical myocardial injury or structural heart disease are unknown.
  5. Autophagy and senescence in fibrosing cholangiopathies

    Journal of Hepatology 62(4):934 (2015)

    Fibrosing cholangiopathy such as primary sclerosing cholangitis (PSC) and biliary atresia (BA) is characterized by biliary epithelial injuries and concentric fibrous obliteration of the biliary tree together with inflammatory cell infiltration. In these diseases, inappropriate innate i...
  6. Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial

    Journal of Hepatology 62(4):822 (2015)

    Background & Aims Albumin infusion improves renal function and survival in cirrhotic patients with spontaneous bacterial peritonitis (SBP) but its efficacy in other types of infections remains unknown. We investigated this issue through a multicenter randomized controlled tri...
  7. Going full circle: Validation of P-body dispersion in hepatitis C virus-infected patients

    Journal of Hepatology 62(4):756 (2015)

  8. Can NASH lipidome provide insight into the pathogenesis of obesity-related non-alcoholic fatty liver disease?

    Journal of Hepatology 62(4):761 (2015)

  9. Outcomes in liver transplantation: Does sex matter?

    Journal of Hepatology 62(4):946 (2015)

    A growing literature has highlighted important differences in transplant-related outcomes between men and women. In the United States there are fewer women than men on the liver transplant waitlist and women are two times less likely to receive a deceased or living-related liver transp...
  10. EASL Monothematic Conference, Autoimmune Hepatitis. London, United Kingdom, 2015
    Author(s) unavailable

    Journal of Hepatology 62(4):ii (2015)

  11. The International Liver CongressTM 2015. Vienna, 50th anniversary
    Author(s) unavailable

    Journal of Hepatology 62(4):vi (2015)

  12. Join EASL. Take an active role in the most forward thinking and dynamic hepatology community worldwide
    Author(s) unavailable

    Journal of Hepatology 62(4):viii (2015)

  13. EASL Special Conference, Addressing End-Stage Liver Disease, a Multifaceted Challenge. Glasgow, United Kingdom, 2015
    Author(s) unavailable

    Journal of Hepatology 62(4):xiv (2015)

  14. Editorial Board
    Author(s) unavailable

    Journal of Hepatology 62(1):i (2015)

  15. 24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis

    Journal of Hepatology 62(4):871 (2015) PMID 25463533 PMCID PMC4368108

    [Display omitted]
  16. Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN-β induction by efficient MAVS cleavage

    Journal of Hepatology 62(4):779 (2015)

    [Display omitted]
  17. Dysregulated miR-124 and miR-200 expression contribute to cholangiocyte proliferation in the cholestatic liver by targeting IL-6/STAT3 signalling

    Journal of Hepatology 62(4):889 (2015)

    [Display omitted]
  18. Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy

    Journal of Hepatology 62(4):956 (2015)

    In the treatment of chronic hepatitis B (CHB), the ultimate goal is preventing hepatitis B virus (HBV)-associated liver disease, including hepatocellular carcinoma (HCC). Recently published studies show that in CHB patients treated with the currently recommended first-line nucleos(t)id...
  19. Reply to: “A scoring system for biliary atresia: Is this the right one?”

    Journal of Hepatology 62(4):986 (2015)

  20. Reply to: “Chronic kidney disease (CKD) and NAFLD: Time for awareness and screening”

    Journal of Hepatology 62(4):984 (2015)